Journal of Cardiovascular Pharmacology and Therapeutics最新文献

{"title":"Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction.","authors":"Sara Leite,&nbsp;Liliana Moreira-Costa,&nbsp;Rui Cerqueira,&nbsp;Cláudia Sousa-Mendes,&nbsp;António Angélico-Gonçalves,&nbsp;Dulce Fontoura,&nbsp;Francisco Vasques-Nóvoa,&nbsp;Adelino F Leite-Moreira,&nbsp;André P Lourenço","doi":"10.1177/10742484211034253","DOIUrl":"https://doi.org/10.1177/10742484211034253","url":null,"abstract":"<p><p>Although decreased protein kinase G (PKG) activity was proposed as potential therapeutic target in heart failure with preserved ejection fraction (HFpEF), randomized clinical trials (RCTs) with type-5 phosphodiesterase inhibitors (PDE5i) showed neutral results. Whether specific subgroups of HFpEF patients may benefit from PDE5i remains to be defined. Our aim was to test chronic sildenafil therapy in the young male ZSF1 obese rat model of HFpEF with severe hypertension and metabolic syndrome. Sixteen-week-old ZSF1 obese rats were randomly assigned to receive sildenafil 100 mg·Kg^-1·d^-1 dissolved in drinking water (ZSF1 Ob SIL, n = 8), or placebo (ZSF1 Ob PL, n = 8). A group of Wistar-Kyoto rats served as control (WKY, n = 8). Four weeks later animals underwent effort tests, glucose metabolism studies, hemodynamic evaluation, and samples were collected for aortic ring preparation, left ventricular (LV) myocardial adenosine triphosphate (ATP) quantification, immunoblotting and histology. ZSF1 Ob PL rats showed systemic hypertension, aortic stiffening, impaired LV relaxation and increased LV stiffness, with preserved ejection fraction and cardiac index. Their endurance capacity was decreased as assessed by maximum workload and peak oxygen consumption (V˙O₂) and respiratory quotient were increased, denoting more reliance on anaerobic metabolism. Additionally, ATP levels were decreased. Chronic sildenafil treatment attenuated hypertension and decreased LV stiffness, modestly enhancing effort tolerance with a concomitant increase in peak, ATP levels and VASP phosphorylation. Chronic sildenafil therapy in this model of HFpEF of the young male with extensive and poorly controlled comorbidities has beneficial cardiovascular effects which support RCTs in HFpEF patient subgroups with similar features.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"690-701"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10742484211034253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39259995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating Acute Myocardial Infarctions With Anti-Inflammatory Agents.","authors":"Robert A Kloner","doi":"10.1177/10742484211033711","DOIUrl":"https://doi.org/10.1177/10742484211033711","url":null,"abstract":"There is an unmet need to further reduce the size of acute myocardial infarctions above and beyond the current standard of care of early reperfusion therapy with primary percutaneous coronary intervention (angioplasty/stenting) and anti-platelet agents to keep the infarct related artery patent. Even a 5% reduction in myocardial infarct size may be clinically meaningful. It is known that the inflammatory process occurs early after coronary artery occlusion/reperfusion with very early influx of neutrophils. There has been concern that if the inflammatory response is too severe it could contribute to additional myocardial cells dying and lead to infarct extension with a larger infarct size. On the other hand, the early inflammatory response is the first step in the healing phase of myocardial infarction. Experimental studies from the 1980s suggested that certain anti-inflammatory medicines, such as steroids and non-steroidal anti-inflammatory agents, such as ibuprofen, administered early during infarction would reduce the size of myocardial infarction. There was considerable excitement about this possibility and clinical studies were planned and some were carried out. However, there was underlying concern that inhibiting the inflammatory cascade early after occlusion might then inhibit the healing phase of acute myocardial infarction. In a series of studies from the early 1980s our research group assessed the effects of methylprednisolone, ibuprofen, and indomethacin on the healing phase of myocardial infarctions. Methylprednisolone was shown to enhance “mummification” of the myocardium whereby large sheets of necrotic, but architecturally preserved muscle fibers remained in the center of the myocardial infarction during the healing phase. Steroids clearly suppressed the process whereby necrotic debris is removed from the infarct and delayed the shrinkage of the scar. Short term administration of methylprednisolone resulted in thinner scars and reduced left ventricular function. Nonsteroidal anti-inflammatory drugs including ibuprofen and indomethacin when administered early and acutely after myocardial infarction contributed to an increase in myocardial infarct expansion, that phenomenon whereby necrotic myocytes thin, stretch, slip by each other resulting in a thin and elongated infarct, thinned scar, regional ventricular dilatation and then global dilatation. This phenomenon of adverse left ventricular remodeling is known to occur in patients, especially those with large infarcts and can contribute to heart failure, myocardial rupture and death. There were a few clinical studies that examined the effect of steroids on myocardial infarct size in which the results were negative; although one meta-analysis suggested corticosteroids did no harm and perhaps improved survival. Clinical trials that tried to impede the function of neutrophils, including their ability to adhere to the walls of blood vessels and trials of anticomplement strategies were neg","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"736-738"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10742484211033711","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39259996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation.","authors":"Bruria Hirsh Raccah, Yevgeni Erlichman, Arthur Pollak, Ilan Matok, Mordechai Muszkat","doi":"10.1177/10742484211019657","DOIUrl":"10.1177/10742484211019657","url":null,"abstract":"<p><strong>Introduction: </strong>Anticoagulants are associated with significant harm when used in error, but there are limited data on potential harm of inappropriate treatment with direct oral anticoagulants (DOACs). We conducted a matched case-control study among atrial fibrillation (AF) patients admitting the hospital with a chronic treatment with DOACs, in order to assess factors associated with the risk of major bleeding.</p><p><strong>Methods: </strong>Patient data were documented using hospital's computerized provider order entry system. Patients identified with major bleeding were defined as cases and were matched with controls based on the duration of treatment with DOACs and number of chronic medications. Appropriateness of prescribing was assessed based on the relevant clinical guidelines. Conditional logistic regression was used to evaluate the potential impact of safety-relevant prescribing errors with DOACs on major bleeding.</p><p><strong>Results: </strong>A total number of 509 eligible admissions were detected during the study period, including 64 cases of major bleeding and 445 controls. The prevalence of prescribing errors with DOACs was 33%. Most prevalent prescribing errors with DOACs were \"drug dose too low\" (16%) and \"non-recommended combination of drugs\" (11%). Safety-relevant prescribing errors with DOACs were associated with major bleeding [adjusted odds ratio (aOR) 2.17, 95% confidence interval (CI) 1.14-4.12].</p><p><strong>Conclusion: </strong>Prescribers should be aware of the potential negative impact of prescribing errors with DOACs and understand the importance of proper prescribing and regular follow-up.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"601-610"},"PeriodicalIF":2.5,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1b/c9/10.1177_10742484211019657.PMC8547237.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38969885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.","authors":"William B White,&nbsp;Adrian Dobs,&nbsp;Culley Carson,&nbsp;Anthony DelConte,&nbsp;Mohit Khera,&nbsp;Martin Miner,&nbsp;Muhammad Shahid,&nbsp;Kilyoung Kim,&nbsp;Nachiappan Chidambaram","doi":"10.1177/10742484211027394","DOIUrl":"https://doi.org/10.1177/10742484211027394","url":null,"abstract":"<p><strong>Background: </strong>Testosterone replacement therapies may increase blood pressure (BP) with chronic use but the mechanism is not clear. TLANDO™ is a new oral testosterone undecanoate (TU) under development for the treatment of male hypogonadism.</p><p><strong>Methods: </strong>We studied the effects of the TU at 225 mg twice daily on ambulatory BP (ABP) and heart rate, in 138 men with hypogonadism (mean age, 54 years, 79% white, 48% with hypertension). Ambulatory BP and heart rate and hematologic assessments were obtained at baseline and following 4-months of therapy.</p><p><strong>Results: </strong>Changes from baseline in ambulatory 24-hour, awake, and sleep systolic BP (SBP) of 3.8 (<i>P</i> < 0.001), 5.2 (<i>P</i> < 0.001), and 4.3 mmHg (<i>P</i> = 0.004) were observed post-treatment, respectively. Lesser changes in the diastolic BP (DBP) were observed (1.2 (<i>P</i> = 0.009), 1.7 (<i>P</i> = 0.004), and 1.7 mmHg (<i>P</i> = 0.011) for 24-hour, awake, and sleep, respectively). Hematocrit and hemoglobin were increased by 3.2% and 0.9 g/dL (<i>P</i> < 0.001), respectively. In those men in the top quartile of changes in hematocrit (range of 6% to 14%), the largest increases in ambulatory SBP (mean, 8.3 mmHg) were observed, whereas the changes in ambulatory SBP in the lower 3 quartiles were smaller (mean, 1.9, 3.3, and 2.1 mmHg in 1st, 2nd and 3 rd quartiles, respectively).</p><p><strong>Conclusion: </strong>These data demonstrate that small increases in ABP occurred following 4 months of the oral TU. For those men whose hematocrit rose by >6%, BP increases were of greater clinical relevance. Hence, hematocrit may aid in predicting the development of BP increases on testosterone therapy.</p><p><strong>Clinicaltrials.gov identifier: </strong>NCT03868059.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"630-637"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10742484211027394","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39123301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension.","authors":"David Mondaca-Ruff,&nbsp;Patricio Araos,&nbsp;Cristián E Yañez,&nbsp;Ulises F Novoa,&nbsp;Italo G Mora,&nbsp;María Paz Ocaranza,&nbsp;Jorge E Jalil","doi":"10.1177/10742484211053109","DOIUrl":"https://doi.org/10.1177/10742484211053109","url":null,"abstract":"<p><strong>Background: </strong>Thiazides are one of the most common antihypertensive drugs used for hypertension treatment and hydrochlorothiazide (HCTZ) is the most frequently used diuretic for hypertension treatment. The Rho/Rho-kinase (ROCK) path plays a key function in cardiovascular remodeling. We hypothesized that in preclinical hypertension HCTZ reduces myocardial ROCK activation and consequent myocardial remodeling.</p><p><strong>Methods: </strong>The preclinical model of deoxycorticosterone (DOCA)-salt hypertension was used (Sprague-Dawley male rats). After 3 weeks, in 3 different groups: HCTZ, the ROCK inhibitor fasudil or spironolactone was added (3 weeks). After 6 weeks myocardial hypertrophy and fibrosis, cardiac levels of profibrotic proteins, mRNA levels (RT PCR) of pro remodeling and pro oxidative molecules and ROCK activity were determined.</p><p><strong>Results: </strong>Blood pressure, myocardial hypertrophy and fibrosis were reduced significantly by HCTZ, fasudil and spironolactone. In the heart, increased levels of the pro-fibrotic proteins Col-I, Col-III and TGF-β1 and gene expression of pro-remodeling molecules TGF-β1, CTGF, MCP-1 and PAI-1 and the pro-oxidative molecules gp91phox and p22phox were significantly reduced by HCTZ, fasudil and spironolactone. ROCK activity in the myocardium was increased by 54% (<i>P</i> < 0.05) as related to the sham group and HCTZ, spironolactone and fasudil, reduced ROCK activation to control levels.</p><p><strong>Conclusions: </strong>HCTZ reduced pathologic LVH by controlling blood pressure, hypertrophy and myocardial fibrosis and by decreasing myocardial ROCK activation, expression of pro remodeling, pro fibrotic and pro oxidative genes. In hypertension, the observed effects of HCTZ on the myocardium might explain preventive outcomes of thiazides in hypertension, specifically on LVH regression and incident heart failure.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"724-735"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39498173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone Deficiency, Long-Term Testosterone Therapy, and Inflammation.","authors":"Xiao Zhang,&nbsp;Hongwei Zhao,&nbsp;Jennifer Horney,&nbsp;Natalie Johnson,&nbsp;Farid Saad,&nbsp;Karim Sultan Haider,&nbsp;Ahmad Haider,&nbsp;Xiaohui Xu","doi":"10.1177/10742484211032402","DOIUrl":"https://doi.org/10.1177/10742484211032402","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to evaluate the association of testosterone deficiency with inflammation and how long-term testosterone therapy affects inflammation biomarkers over time.</p><p><strong>Methods: </strong>We conducted a 2-component study. First, we conducted a cross-sectional study using the recently released 2015-2016 National Health and Nutrition Examination Survey (NHANES) data to examine the association between testosterone deficiency and inflammation biomarkers including high sensitivity C-reactive protein (hsCRP), liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the US general population. Then we conducted a longitudinal study to investigate the longitudinal effect of testosterone therapy on inflammation biomarkers and the risk of cardiovascular events, using data from 776 hypogonadal men based on a registry study in Germany with up to 11 years' follow-up.</p><p><strong>Results: </strong>The adjusted odds ratios (ORs) describing the associations between testosterone deficiency and hsCRP ≥ 3mg/L, ALT > 40U/L, and AST > 40U/L were 1.81 (<i>P</i>-value < 0.001), 1.46 (<i>P</i>-value = 0.009), and 0.99 (<i>P</i>-value = 0.971), respectively. In the control group, CRP, ALT, and AST levels increased by 0.003 (95%CI: -0.001, 0.007) mg/L, 0.157 U/L (95%CI: 0.145, 0.170), and 0.147 (95%CI: 0.136, 0.159) U/L per month, while in the treatment group, CRP, ALT, and AST levels decreased by 0.05 (95%CI: -0.055, -0.046) mg/L, 0.142 U/L (95%CI: -0.154, -0.130), and 0.148 (95%CI: -0.158, -0.137) U/L per month.</p><p><strong>Conclusion: </strong>Testosterone deficiency was associated with an increased level of inflammation; long-term testosterone therapy alleviated inflammation among hypogonadal men, which may contribute to the reduced cardiovascular risk. Future large trials are warranted to confirm our observational study findings.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"638-647"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10742484211032402","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39172356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction.","authors":"David J Cordwin,&nbsp;Theodore J Berei,&nbsp;Kristen T Pogue","doi":"10.1177/10742484211042706","DOIUrl":"https://doi.org/10.1177/10742484211042706","url":null,"abstract":"<p><p>Over the past decade, soluble guanylate cyclase (sGC) activators and stimulators have been developed and studied to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The sGC enzyme plays an important role in the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway, that has been largely untargeted by current guideline directed medical therapy (GDMT) for HFrEF. Disruption of the NO-sCG-cGMP pathway can be widely observed in patients with HFrEF leading to endothelial dysfunction. The disruption is caused by an oxidized state resulting in low bioavailability of NO and cGMP. The increase in reactive oxygen species can also result in an oxidized, and subsequently heme free, sGC enzyme that NO is unable to activate, furthering the endothelial dysfunction. The novel sGC stimulators enhance the sensitivity of sGC to NO, and independently stimulate sGC, while the sGC activators target the oxidized and heme free sGC to stimulate cGMP production. This review will discuss the pathophysiologic basis for sGC stimulator and activator use in HFrEF, review the pre-clinical and clinical data, and propose a place in the HFrEF armamentarium for this novel pharmacotherapeutic class.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"593-600"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39388090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The β₃ Adrenergic Receptor Antagonist L-748,337 Attenuates Dobutamine-Induced Cardiac Inefficiency While Preserving Inotropy in Anesthetized Pigs.","authors":"Lars Rødland,&nbsp;Leif Rønning,&nbsp;Anders Benjamin Kildal,&nbsp;Ole-Jakob How","doi":"10.1177/10742484211048762","DOIUrl":"https://doi.org/10.1177/10742484211048762","url":null,"abstract":"<p><p>Excessive myocardial oxygen consumption (MVO₂) is considered a limitation for catecholamines, termed oxygen cost of contractility. We hypothesize that increased MVO₂ induced by dobutamine is not directly related to contractility but linked to intermediary myocardial metabolism. Furthermore, we hypothesize that selective β₃ adrenergic receptor (β₃AR) antagonism using L-748,337 prevents this. In an open-chest pig model, using general anesthesia, we assessed cardiac energetics, hemodynamics and arterial metabolic substrate levels at baseline, ½ hour and 6 hours after onset of drug infusion. Cardiac efficiency was assessed by relating MVO₂ to left ventricular work (PVA; pressure-volume area). Three groups received dobutamine (5 μg/kg/min), dobutamine + L-748,337 (bolus 50 μg/kg), or saline for time-matched controls. Cardiac efficiency was impaired over time with dobutamine infusion, displayed by persistently increased unloaded MVO₂ from ½ hour and 47% increase in the slope of the PVA-MVO₂ relation after 6 hours. Contractility increased immediately with dobutamine infusion (<i>dP</i>/<i>dt</i>_max; 1636 ± 478 vs 2888 ± 818 mmHg/s, <i>P</i> < 0.05) and persisted throughout the protocol (2864 ± 1055 mmHg/s, <i>P</i> < 0.05). Arterial free fatty acid increased gradually (0.22 ± 0.13 vs 0.39 ± 0.30 mM, <i>P</i> < 0.05) with peak levels after 6 hours (1.1 ± 0.4 mM, <i>P</i> < 0.05). By combining dobutamine with L-748,337 the progressive impairment in cardiac efficiency was attenuated. Interestingly, this combined treatment effect occurred despite similar alterations in cardiac inotropy and substrate supply. We conclude that the extent of cardiac inefficiency following adrenergic stimulation is dependent on the duration of drug infusion, and β₃AR blockade may attenuate this effect.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"714-723"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39440361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Body Mass Index With Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.","authors":"Kazuhiko Kido,&nbsp;Christopher Bianco,&nbsp;Marco Caccamo,&nbsp;Wei Fang,&nbsp;George Sokos","doi":"10.1177/10742484211024441","DOIUrl":"https://doi.org/10.1177/10742484211024441","url":null,"abstract":"<p><strong>Background: </strong>Only limited data are available that address the association between body mass index (BMI) and clinical outcomes in patients with heart failure with reduced ejection fraction who are receiving sacubitril/valsartan.</p><p><strong>Methods: </strong>We performed a retrospective multi-center cohort study in which we compared 3 body mass index groups (normal, overweight and obese groups) in patients with heart failure with reduced ejection fraction receiving sacubitril/valsartan. The follow-up period was at least 1 year. Propensity score weighting was performed. The primary outcomes were hospitalization for heart failure and all-cause mortality.</p><p><strong>Results: </strong>Of the 721 patients in the original cohort, propensity score weighting generated a cohort of 540 patients in 3 groups: normal weight (n = 78), overweight (n = 181), and obese (n = 281). All baseline characteristics were well-balanced between 3 groups after propensity score weighting. Among our results, we found no significant differences in hospitalization for heart failure (normal weight versus overweight: average hazard ratio [AHR] 1.29, 95% confidence interval [CI] = 0.76-2.20, <i>P</i> = 0.35; normal weight versus obese: AHR 1.04, 95% CI = 0.63-1.70, <i>P</i> = 0.88; overweight versus obese groups: AHR 0.81, 95% CI = 0.54-1.20, <i>P</i> = 0.29) or all-cause mortality (normal weight versus overweight: AHR 0.99, 95% CI = 0.59-1.67, <i>P</i> = 0.97; normal weight versus obese: AHR 0.87, 95% CI = 0.53-1.42, <i>P</i> = 0.57; overweight versus obese: AHR 0.87, 95% CI = 0.58-1.32, <i>P</i> = 0.52).</p><p><strong>Conclusion: </strong>We identified no significant associations between BMI and clinical outcomes in patients diagnosed with heart failure with a reduced ejection fraction who were treated with sacubitril/valsartan. A large-scale study should be performed to verify these results.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"619-624"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10742484211024441","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39246500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlling Reperfusion Injury With Controlled Reperfusion: Historical Perspectives and New Paradigms.","authors":"Demetria M Fischesser,&nbsp;Bin Bo,&nbsp;Rachel P Benton,&nbsp;Haili Su,&nbsp;Newsha Jahanpanah,&nbsp;Kevin J Haworth","doi":"10.1177/10742484211046674","DOIUrl":"https://doi.org/10.1177/10742484211046674","url":null,"abstract":"<p><p>Cardiac reperfusion injury is a well-established outcome following treatment of acute myocardial infarction and other types of ischemic heart conditions. Numerous cardioprotection protocols and therapies have been pursued with success in pre-clinical models. Unfortunately, there has been lack of successful large-scale clinical translation, perhaps in part due to the multiple pathways that reperfusion can contribute to cell death. The search continues for new cardioprotection protocols based on what has been learned from past results. One class of cardioprotection protocols that remain under active investigation is that of controlled reperfusion. This class consists of those approaches that modify, in a controlled manner, the content of the reperfusate or the mechanical properties of the reperfusate (e.g., pressure and flow). This review article first provides a basic overview of the primary pathways to cell death that have the potential to be addressed by various forms of controlled reperfusion, including no-reflow phenomenon, ion imbalances (particularly calcium overload), and oxidative stress. Descriptions of various controlled reperfusion approaches are described, along with summaries of both mechanistic and outcome-oriented studies at the pre-clinical and clinical phases. This review will constrain itself to approaches that modify endogenously-occurring blood components. These approaches include ischemic postconditioning, gentle reperfusion, controlled hypoxic reperfusion, controlled hyperoxic reperfusion, controlled acidotic reperfusion, and controlled ionic reperfusion. This review concludes with a discussion of the limitations of past approaches and how they point to potential directions of investigation for the future.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"26 6","pages":"504-523"},"PeriodicalIF":2.6,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960123/pdf/nihms-1785650.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39426883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}